Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q3 2023 revenue $25.2 million, 34% y/y growth
Reiterating FY 2023 revenue guidance range of $95-98 million
MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq:AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2023.
Related news for (AKYA)
- Today’s Top Performers: MoBot’s Market Review 05/21/25 08:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/21/25 07:00 AM
- Akoya Biosciences Reports First Quarter 2025 Financial Results
- Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
- Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025